OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Shah on Research to Minimize Surgical Intervention in Locoregional Breast Cancer

July 23rd 2024

Chirag Shah, MD, discusses ongoing clinical trials aiming to minimize surgical intervention in locoregional breast cancer.

Dr Mouabbi on Clinical Trials for Invasive Lobular Breast Cancer

July 23rd 2024

Jason A. Mouabbi, MD, discusses clinical trials aimed at expanding the treatment paradigm for invasive lobular breast cancer.

Dr Li on Unmet Needs in High-Risk MIBC

July 23rd 2024

Roger Li, MD, discusses persisting unmet needs in high-risk, muscle-invasive bladder cancer.

Dr Franses on the Need for Prospective Data in Second-Line HCC and Beyond

July 23rd 2024

Joseph Franses, MD, PhD, discusses the need for more prospective data in the second-line setting and beyond for patients with hepatocellular carcinoma.

Dr Rini on the Background of a Biomarker Analysis of KEYNOTE-426 in RCC

July 23rd 2024

Brian I. Rini, MD, FASCO, discusses an analysis of clustering from the KEYNOTE-426 study in patients with advanced renal cell carcinoma.

Dr Grimm on the Rationale for Conducting a Post-Hoc Analysis of ARASENS in mHSPC

July 23rd 2024

Marc-Oliver Grimm, MD, discusses a post-hoc analysis of the ARASENS trial in metastatic hormone-sensitive prostate cancer.

Dr Siegel on the Need for Durable Remissions in Patients With Multiple Myeloma

July 23rd 2024

David Samuel Dicapua Siegel, MD, discusses unmet needs and current challenges within multiple myeloma.

Dr Fürstenau on the Rationale for the GAIA/CLL13 Trial in Previously Untreated CLL

July 23rd 2024

Moritz Fürstenau, MD, discusses the rationale for launching the phase 3 GAIA/CLL13 in previously untreated, fit patients with chronic lymphocytic leukemia.

Dr Gandhi on Considerations for Continuing CDK4/6 Inhibitors After Progression in HR+ Advanced Breast Cancer

July 22nd 2024

Shipra Gandhi, MD, discusses considerations for continuing with a CDK4/6 inhibitor or switching therapies in HER2- negative advanced breast cancer.

Dr Liao on Selecting Between First-Line Monotherapy and Combination Approaches in HCC

July 22nd 2024

Chih-Yi Liao, MD, discusses key considerations for the selection of single-agent vs combination regimens in frontline metastatic hepatocellular carcinoma.

Dr Shadman on the Evaluation of Zanbrutinib Plus Sonrotoclax in Treatment-Naive CLL

July 22nd 2024

Mazyar Shadman, MD, MPH, discusses the rationale for combining sonrotoclax plus zanubrutinib for treatment-naive chronic lymphocytic leukemia.

Dr Feldman on New Approaches for Decreasing the Risk of Breast Cancer–Related Lymphedema

July 20th 2024

Sheldon Feldman, MD discusses new approaches for decreasing the risk of and managing breast cancer¬–related lymphedema.

Dr Mukhtar on Challenges in the Diagnosis and Management of Invasive Lobular Carcinoma

July 20th 2024

Rita Mukhtar, MD, discusses challenges in the diagnosis and management of invasive lobular carcinoma.

Dr Pusztai on Molecular Residual Disease Monitoring in Early Breast Cancer

July 20th 2024

Lajos Pusztai, MD, DPhil, discusses the progress and challenges in monitoring molecular residual disease in early breast cancer.

Dr Rugo on Managing Treatment-Limiting Toxicities in Breast Cancer

July 19th 2024

Hope S. Rugo, MD discusses managing treatment-related toxicities within the scope of the current breast cancer treatment paradigm.

Dr Franses on Considerations for Second-Line Treatment of HCC

July 19th 2024

Joseph Franses, MD, PhD, discusses treatment considerations for hepatocellular carcinoma that progresses after first-line therapy.

Dr Machaalani on Overcoming Acquired Resistance Through AXL and c-Met Inhibition in RCC

July 19th 2024

Marc Machaalani, MD, discusses how inhibition of AXL and c-Met may prevent acquired resistance to c-Met inhibitors in renal cell carcinoma.

Dr Eckfeldt on the Implications of Improved MRD Testing in AML

July 19th 2024

Craig Eckfeldt, MD, PhD, discusses how improved minimal residual disease testing methods have impacted the acute myeloid leukemia treatment paradigm.

Dr Morgans on the Importance of Detecting Radiographic Progression in nmCRPC

July 19th 2024

Alicia Morgans, MD, MPH, discusses data from the ARAMIS trial showing the association between PSA levels and radiological progression in nmCRPC.

Dr Garfall on Updated Safety Data for Teclistamab in R/R Myeloma

July 18th 2024

Alfred L. Garfall, MD, MS, discusses updated safety data for teclistamab in relapsed/refractory multiple myeloma.